Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 27;14(1):4786.
doi: 10.1038/s41598-024-55262-8.

Protective effect of microbisporicin (NAI-107) against vancomycin resistant Enterococcus faecium infection in a Galleria mellonella model

Affiliations

Protective effect of microbisporicin (NAI-107) against vancomycin resistant Enterococcus faecium infection in a Galleria mellonella model

Nele Hofkens et al. Sci Rep. .

Abstract

Increasing antimicrobial resistance in Enterococcus faecium necessitates the search for novel treatment agents, such as bacteriocins. In this study, we conducted an in vivo assessment of five bacteriocins, namely Lacticin Z, Lacticin Q, Garvicin KS (ABC), Aureocin A53 and Microbisporicin (NAI-107), against vanB-resistant Enterococcus faecium using a Galleria mellonella model. Our in vitro experiments demonstrated the efficacy of all five bacteriocins against vanB-resistant E. faecium with only NAI-107 demonstrating in vivo efficacy. Notably, NAI-107 exhibited efficacy across a range of tested doses, with the highest efficacy observed at a concentration of 16 µg/mL. Mortality rates in the group treated with 16 µg/mL NAI-107 were lower than those observed in the linezolid-treated group. These findings strongly suggest that NAI-107 holds promise as a potential alternative therapeutic agent for treating infections caused by resistant E. faecium and warrants further investigation.

Keywords: Enterococcus faecium; Galleria mellonella; Lantibiotics; Microbisporicin; NAI-107; VanB.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Overview of the in vivo assay in Galleria mellonella model. (Figure was generated using BioRender).
Figure 2
Figure 2
Efficacy of (a) Aureocin A53 (2, 8, and 16 µg/mL) and Linezolid (10 µg/mL) (b) Garvicin KS ABC (4, 8, and 16 µg/mL) (c) Lacticin Q (4, 8, and 16 µg/mL) and (d) Lacticin Z (2, 4, 8, and 16 µg/mL) treatment on G. mellonella larvae. A Negative control group was injected with 30 µL of PBS, and a positive control group was inoculated with 30 µL of PBS containing 2.7 × 107 CFUs of the E. faecium strain. Both test and control groups consisted of 20 larvae and were incubated for 120 h at 37 °C. Symbols represent mean survival of the G. mellonella. *P < 0.01, **P < 0.001, ***P < 0.0001, ****P < 0.00001.
Figure 3
Figure 3
Effectiveness of Microbisporicin (2, 4, 8 and 16 µg/mL) and Linezolid (10 µg/mL) treatments on G. mellonella larvae. A negative control group was injected with 30 µL of PBS, and a positive control group was inoculated with 30 µL of PBS containing 2.7 × 107 CFUs of the E. faecium strain. Both test and control groups consisted of 20 larvae and were incubated for 120 h at 37 °C. Symbols represent mean survival of the G. mellonella. *P < 0.01, **P < 0.001, ***P < 0.0001, ****P < 0.00001.

Similar articles

Cited by

References

    1. Uttley A, et al. High-level vancomycin-resistant enterococci causing hospital infections. Epidemiol. Infect. 1989;103(1):173–181. doi: 10.1017/S0950268800030478. - DOI - PMC - PubMed
    1. Fisher K, Phillips C. The ecology, epidemiology and virulence of Enterococcus. Microbiology. 2009;155(6):1749–1757. doi: 10.1099/mic.0.026385-0. - DOI - PubMed
    1. Ramsey AM, Zilberberg MD. Secular trends of hospitalization with vancomycin-resistant enterococcus infection in the United States, 2000–2006. Infect. Control Hosp. Epidemiol. 2009;30(2):184–186. doi: 10.1086/593956. - DOI - PubMed
    1. Hidron AI, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: Annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infect. Control Hosp. Epidemiol. 2008;29(11):996–1011. doi: 10.1086/591861. - DOI - PubMed
    1. Ahmed MO, Baptiste KE. Vancomycin-resistant enterococci: A review of antimicrobial resistance mechanisms and perspectives of human and animal health. Microb. Drug Resist. 2018;24(5):590–606. doi: 10.1089/mdr.2017.0147. - DOI - PubMed

MeSH terms